The funding is being used to advance the development of Rejuvenate’s lead candidate RJx-01 in both acute and chronic sarcopenia. The round was led by Vesalius Biocapital III.
Rejuvenate Biomed held its first Clinical Advisory Board to evaluate the clinical development plan for RJx-01 as a safe therapeutic to treat sarcopenia.
Rejuvenate Biomed collaborates under a Cooperative Research & Development Agreement (CRADA) with Dr. Rafael de Cabo, MD, PhD, Professor at the NIA`s Translational Gerontology Branch.
Rejuvenate Biomed's SAB concluded that our data do not only provide POP for sarcopenia, but demonstrate multiple opportunities in other muscle- and non-muscle-related disorders.